JTCS Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rascoe, P. A.
Right arrow Articles by Smythe, W. R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Rascoe, P. A.
Right arrow Articles by Smythe, W. R.
Related Collections
Right arrow Pleura
Right arrow Molecular biology
Right arrowRelated Article

J Thorac Cardiovasc Surg 2006;131:510
© 2006 The American Association for Thoracic Surgery

Letter to the Editor

Reply to the Editor

Philip A. Rascoe, MD, Xiaobo Cao, MD, Jonathan C. Daniel, MD, Steven D. Miller, MD, W. Roy Smythe, MD

M.D. Anderson Cancer Center, Houston, TX 77030

We greatly appreciate the kind remarks and insightful comments by Konstantinov, Li, and Reddington concerning our recent manuscript, "Receptor Tyrosine Kinase and Phosphoinositide-3 Kinase Signaling in Malignant Mesothelioma."

Although constitutive activation of the PI3K/Akt pathway has been demonstrated in a number of solid malignancies, its importance is certainly not limited to neoplastic cells. In fact, Akt signaling enhances vital cellular processes such as glycogen synthesis and nitric oxide production. LY294002 is a lead compound in the development of PI3K inhibitors and is not available for human trials. However, we believe that further drug development could possibly produce a compound with acceptable toxicity and therapeutic potential in oncology. We agree that any new interventions must be applied with caution in the context of a controlled trial.

Similarly, inhibitors of the insulin-like growth factor receptor are still in the developmental phase. While such compounds have potential as antineoplastic agents, there is also the potential for toxic effects such as the development of endocrinopathies. However, inhibitors of receptor tyrosine kinases such as epidermal growth factor receptor (Iressa, Tarceva) and platelet-derived growth factor receptor (Gleevec) are currently used in the treatment of solid and hematologic malignant tumors with acceptable side effect profiles.

We again thank Konstantinov, Li, and Reddington for their interest in our work. It is clear that an understanding of molecular mechanisms will be requisite for contemporary clinicians, particularly those treating cardiovascular and oncologic disease.


Related Article

From mesothelioma to cardiovascular protection via the phosphoinositide-3 kinase pathway: A new vista in cardiothoracic surgery
Igor E. Konstantinov, Jia Li, and Andrew N. Redington
J. Thorac. Cardiovasc. Surg. 2006 131: 509-510. [Extract] [Full Text] [PDF]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rascoe, P. A.
Right arrow Articles by Smythe, W. R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Rascoe, P. A.
Right arrow Articles by Smythe, W. R.
Related Collections
Right arrow Pleura
Right arrow Molecular biology
Right arrowRelated Article

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS